Anthem Biosciences Ltd is an Indian player in possibly one of the most competitive fields of CRDMO (Contract Research, Development, and Manufacturing Organization) that combines innovation-based pharmaceutical research with the scale of commercial manufacturing. Anthem Biosciences Share Price is best for Long-Term Investment for Future. During a period whereby, global pharma and biotech firms are increasingly offshoring complex R&D and manufacturing operations, Anthem Biosciences has been able to position itself as a high quality, end to end partner in the drug lifecycle.
The company is listed on Indian stock exchanges with a large-cap valuation, and it has been the focus of long-term investor interest since it has managed to achieve high returns and low return ratios, has an almost debt-free balance sheet, and has exposure to advanced therapeutic designs. Simultaneously, its high valuation and unpaid dividends elevate some significant concerns to investors considering long-term entry points. This article will discuss Anthem Biosciences share price, financial status, valuation, risks, and future prospects.
Anthem Biosciences Ltd Company Overview
Anthem Biosciences Ltd is a privately incorporated company that started in 2006 and has become a fully integrated CRDMO with services provided in drug discovery, development, and commercial manufacturing. Anthem functions along the whole pharmaceutical value-chain (early-stage research through late-stage clinical and commercial supply) unlike traditional contract manufacturers, which only deal with scale production.
The company belongs to a small of Indian companies that is able to cover both New Chemical Entities (NCEs) and New Biological Entities (NBEs). This two-fold potential has greatly broadened its target market and thus has the ability to cater to both small biotech innovators and large pharmaceutical corporations around the globe.
| Particular | Details |
| Company Name | Anthem Biosciences Ltd |
| Year of Incorporation | 2006 |
| Sector | Pharmaceuticals & Biotechnology |
| Industry | CRDMO / Biotechnology |
| Core Focus | NCE & NBE programs |
| Platforms | RNAi, ADCs, peptides, oligonucleotides |
| Listings | NSE & BSE |
| Market Capitalisation | ~₹33,657 crore |
Market Position and Industry Context
The CRDMO industry is achieving good impetus in the world as the pharmaceutical and biotechnology firms are increasingly outsourcing their research and manufacturing in order to cope with the increasing cost of research and development and increasing complexity of drugs. Companies are shifting towards in-house research models which are heavy in assets and to a model of flexible collaboration with specialized service providers. Anthem Biosciences is one of the most distinguished companies in this context because of its comprehensive services, operating margins that are significantly elevated, the capacity to deal with complex chemistry and sophisticated biologics, and alignability with the international regulatory practices. In India, the company has an elite position in CRDMO offering not only a price competition but also a scientific experience, quality of work, and long-term business relations.
Anthem Biosciences Share Price and Valuation Overview
On 30 January, the share price of Anthem Biosciences stood at approximately 599 and it only experienced a slight short-term movement but still was lower than the 52-week high of 874. The stock has high multiple of value, which signifies the market anticipation of a continued growth and dominance in high-technology biotech production. Although the valuation might seem high on conventional measure, investors usually explain it by high earnings sightlines, high margins, and efficiency of capital.
| Metric | Value |
| Current Price | ₹599 |
| Market Capitalisation | ₹33,657 crore |
| 52-Week High | ₹874 |
| 52-Week Low | ₹580 |
| P/E Ratio | ~72.7 |
| Book Value | ₹49 |
| Price to Book | ~12.2x |
| Dividend Yield | 0.00% |
| ROCE | 28.5% |
| ROE | 20.8% |
Anthem Biosciences NSE Price
Anthem Biosciences is trading at ₹597.90, near the National Stock Exchange (NSE) indicating no major changes in demand despite short-term changes. The stock has lately traded in a tight range of 580.50-601.40, indicating that the stock consolidated following preceding post-IPO rallies. Having a market capitalization of approximately 33,300 crore, Anthem is still among the bigger and the most closely monitored CRDMO listing in India.
| Particular | Details |
| NSE Symbol | ANTHEM |
| Latest Close | ₹597.90 |
| Day Range | ₹580.50 – ₹601.40 |
| Average Price | ₹594–₹597 |
| Market Capitalisation | ~₹33,300 Cr |
| Trend | Range-bound / Stable |
Anthem Biosciences BSE Price Today
Anthem Biosciences price movement is closely associated with the NSE on the Bombay Stock Exchange (BSE) which means that there is efficient price discovery among the exchanges. The shares have recently traded at an initial price of 584, intraday highs of 602.40, and intraday lows of 580.65. The intraday momentum has been mostly on the positive side but the stock is trading below its 50 day moving average of approximately ₹642 which is currently serving as a technical resistance.
| Particular | Details |
| BSE Code | 544449 |
| Open Price | ₹584 |
| Day High | ₹602.40 |
| Day Low | ₹580.65 |
| Session Average | ~₹594.63 |
| 50-Day Moving Avg | ~₹642 |
Anthem Biosciences Ltd IPO Details
The IPO of Anthem Biosciences opened on July 14, 2025, closed on July 16 and the listing took place on July 21, 2025. This was highly responded by the investors with an overall subscription of about 63.9 times, which indicates that they were very optimistic about the CRDMO business model of the company. The IPO was done at a face value of 2 and issued 5.96 crore shares that raised about 3395 crore.
| IPO Particular | Information |
| IPO Open Date | July 14, 2025 |
| IPO Close Date | July 16, 2025 |
| Listing Date | July 21, 2025 |
| Issue Size | ₹3,395 Cr |
| Shares Issued | 5.96 Cr |
| Face Value | ₹2 |
| Subscription | 63.86× |
Anthem Biosciences IPO Share Price and Listing Performance
A band of ₹540-₹570 under priced Anthem Biosciences, with the issue being priced at the top price of ₹570. The minimum lot of shares that retail investors had to apply for was 26 shares which corresponded to a minimum investment of approximately 14,040. The stock was listed at a high premium of approximately 28 times on listing day and opened close to 723 -731 on NSE, indicating healthy demand both among institutional and retail shareholders.
| Particular | Details |
| Issue Price | ₹570 |
| Price Band | ₹540 – ₹570 |
| Lot Size | 26 shares |
| Min Retail Investment | ~₹14,040 |
| Listing Price (NSE) | ~₹731 |
| Listing Gain | ~28% |
Anthem Biosciences Share Price Targets (12-Month View)
Share Price Targets (12-Month View).
Brokerage and analyst estimates indicate the possibility of moderate upside in the coming 12 months due to great revenue visibility and high-margin CRDMO operations. Analysts project that the average one-year target will be around 765 with an optimistic estimate of 798. These targets presuppose further contract procurement, maintenance of global R&D budget, and marginability.
| Metric | Value |
| Average Target | ₹765 |
| High Target | ₹798 |
| Upside Bias | Moderate |
| Key Driver | R&D contracts & margin strength |
Anthem Biosciences Share Price Long-Term Targets (2026–2030)
Future estimates of Anthem Biosciences are broad and encompass both future optimism on the biotech outsourcing boom and price-related pessimism. The conservative forecasts of 2026 will lie between 780 and 860, and those of 2030 will be between 1020 and 1500. The estimates are preliminary and are based on the increase in earnings, the demand of biotech globally and the possibility of the company to scale up advanced platforms profitably.
| Year | Minimum Target (₹) | Maximum Target (₹) |
| 2026 | 780 | 860 |
| 2030 | 1,020 | 1,500 |
Note: These are estimates rather than guarantees. The real performance is based on the growth of earnings, the market trends and the industry trends.
Anthem Biosciences Share Quarterly Financial Performance
Anthem Biosciences has presented traditionally good quarterly results, backed by high operating leverage and stable demand among international customers. The company has had operating margins that have been above industry averages and most of the time, they have been over 35-40, which indicates the pricing power and efficiency of the company.
The last quarters indicated a further increase of revenues and increase of profits with variability in tax rates and expenses on depreciation associated with the capacity investments.
| Quarter | Revenue (₹ Cr) | Operating Profit (₹ Cr) | Net Profit (₹ Cr) | OPM |
| Jun 2024 | 339 | 121 | 82 | 36% |
| Sep 2024 | 525 | 195 | 162 | 37% |
| Mar 2025 | 483 | 195 | 83 | 40% |
| Jun 2025 | 540 | 191 | 136 | 35% |
| Sep 2025 | 550 | 218 | 173 | 40% |
Anthem Biosciences Ltd Annual Profit & Loss Performance
Anthem Biosciences has shown a high and comparatively consistent growth on a long-term basis as revenue and profits grow at nourishing rates. The five year gain on the company has been approximately 37 percent on the profit and the sales have been growing well.
Notably, growth has not come at the expense of margins, Anthem has been able to grow with a high level of operating profitability, this is not a common feature in the pharmaceutical services industry.
| Year | Revenue (₹ Cr) | Operating Profit (₹ Cr) | Net Profit (₹ Cr) |
| FY20 | 633 | 182 | 93 |
| FY21 | 1,103 | 408 | 271 |
| FY22 | 1,231 | 565 | 406 |
| FY23 | 1,057 | 431 | 385 |
| FY24 | 1,419 | 506 | 367 |
| FY25 | 1,845 | 672 | 451 |
Anthem Biosciences Ltd Balance Sheet Strength
The clean and conservative balance sheet of Anthem Biosciences is one of the strongest differentiators of the firm. The firm has been gradually cutting down on debt and now it is practically debt free and this has provided it with the room to invest in new platforms, capacity building and takeovers without having to struggle with their finances.
Nobody wants to pay out to shareholders aggressively, but they are making a rise in reserves and retained earnings internally.
| Item (₹ Cr) | FY23 | FY24 | FY25 | Sep 2025 |
| Equity Capital | 112 | 112 | 112 | 112 |
| Reserves | 1,627 | 1,813 | 2,298 | 2,640 |
| Borrowings | 126 | 239 | 113 | 108 |
| Total Assets | 2,014 | 2,398 | 2,808 | 3,284 |
Anthem Biosciences Ltd Cash Flow Analysis
Anthem Biosciences has high-quality earnings indicated by high operating cash flows generated on a regular basis. Cash flow operating has been positive and through the cycle easily financing capital expenditure and selective investments. Negative investing cash flows are considerably capacity expansion and platform development whereas financing outflows are debt repayment as opposed to stress.
| Year | Operating CF | Investing CF | Financing CF |
| FY23 | 306 | -376 | 64 |
| FY24 | 140 | -221 | -77 |
| FY25 | 418 | -152 | -134 |
Anthem Biosciences Ltd Key Financial Ratios
Moreover, the Indian pharmaceutical services environment is one that has outstanding profitability rates of Anthem based on the ratio of returns, a factor that highlights effective capital utilization and pricing strength.
| Ratio | Value |
| ROCE | 28.5% |
| ROE | 20.8% |
| Debt-to-Equity | Very low |
| OPM | ~36–40% |
| Working Capital Days | Elevated but stable |
Anthem Biosciences Ltd Shareholding Pattern and Governance
The holding of the promoters is also high at approximately 74.7, which is an indication of high promoter confidence and long-term commitment. There has been a progressive rise in institutional participation especially that by domestic institutions, though retail holding has been moderate. There is no promoter pledging and no stable ownership structure, which reinforces the perception of good governance.
| Category | Holding (%) |
| Promoters | 74.69% |
| FIIs | 1.37% |
| DIIs | 7.60% |
| Public | 16.34% |
| Shareholders | ~2.0 lakh |
Anthem Biosciences Ltd Share Peer Comparison
Furthermore, Anthem Biotech and CRM A command a valuation premium compared to their listed peers, supported by better margins, a stronger balance sheet, and broader platform exposure.
| Company | P/E | ROCE | Market Cap (₹ Cr) |
| Anthem Biosciences | ~73 | 28.5% | 33,657 |
| Advanced Enzyme | ~23 | 13% | 3,322 |
| Other listed peers | Lower | Lower | Much smaller |
Risks and Concerns
Though the fundamentals are good, Anthem Biosciences is exposed to a number of risks:
- Valuation risk is high and there is no room to play.
- Reliance on pharma R&D cycles at the global scale.
- No dividend payment, which can put off income investors.
- Risks associated with pharma manufacturing are regulatory and compliance risks.
- Any reduction in world biotech funding would have a short-lived effect on growth impotence.
Future Outlook
The long-term perspective of Anthem Biosciences is structurally good. Driven by the need for cost efficiency and the rising complexity of drug development, pharmaceutical firms are increasingly turning to external partners for R&D and manufacturing support.
Anthem has a high profile in terms of returns, a strong balance sheet, and with its advanced technology platforms; it stands well to be a core long term compounder as long as execution is not compromised.
Conclusion
Anthem Biosciences Ltd is a high-quality CRDMO company, which has an entirely integrated drug discovery, development, and manufacturing capacity. Its access to the up-to-date platforms like RNAi, ADCs and peptides puts it in a good position to capitalize on the long-term trends of global outsourcing in the pharmaceutical and biotechnology industry. A sustained high operating margins, high ROCE as well as ROE, and almost debt-free balance sheet is indicative of efficient execution and financial discipline. The stock is however priced above its intrinsic value and is not paying out dividends at the moment hence it suits long term growth oriented investors who are willing to take up valuation risk.
FAQs
Anthem Biosciences offers services on contract research, development and manufacturing of pharmaceutical and biotech companies worldwide in both NCE and NBE programs.
The company has end to end CRDMO services and focuses on high barrier entry platforms such as RNAi, ADCs, peptides, and oligonucleotides.
As a result, Anthem Biosciences has greatly decreased its debt and is currently practically free of debt, allowing it to have high financial flexibility.
No, the company does not pay any dividends now, and it reinvests profits into the capacity expansion and sophisticated research platforms.
Yes, it can be a good investment with long-term investors who want to have an exposure to biotech and CRDMO growth as long as they are not put off by its high premium price and growth-oriented approach.
Read More:
Rndcoin.Kr Blockchain (2025): Features, Pros and Cons, Future Growth, Price Listings and more
